IVI Introduces Transparent Approach for Value Assessment
The Innovation and Value Initiative (IVI) released its first assessment of treatments for rheumatoid arthritis using its new approach toward value assessment. NPC is still evaluating IVI’s new framework and methodology, but we are cautiously optimistic about several attributes of IVI’s approach.
Where Are They Now: Checking In With Former NPC Fellow Chuck Shih
Chuck Shih, PhD, MHS, currently Associate Director, Healthcare Reform and Public Policy at Biogen, was the 2013-2015 NPC Health Policy Fellow as part of a partnership with the George Washington University Milken Institute School of Public Health. Dr. Shih chatted with us about how his time at NPC impacted his work and career.
Information Wanted: Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers
A new white paper highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population coverage decisions for formularies and care pathways.